



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



LETTER TO THE EDITOR

Outcomes of COVID-19 patients treated with noninvasive respiratory support outside-ICU setting: a Portuguese reality



To the Editor

Noninvasive respiratory support (NRS) has become a valuable tool in COVID-19 acute respiratory failure (ARF) management. However, there is a lack of consensus in for or against its use due to the risks of intubation delay and aerosols environmental contamination.¹ Strategies to mitigate NRS iatrogenic risks and healthcare workers infection have been suggested.^{2,3}

Despite efforts to increase ICU resources, to cope with patient influx, general wards worldwide were converted in respiratory intermediate care units (RICU), where patients in need for NRS were treated.^{4,5} Our goal was to evaluate the Portuguese reality regarding safeness and outcomes of NRS in COVID-19 ARF in a non-ICU setting.

Adult patients with COVID-19 pneumonia needing NRS [high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP) and/or noninvasive ventilation (NIV)], treated in a RICU, were prospectively enrolled from November 18th, 2020 to February 18th, 2021. Institutional review boards authorised the study (n. 22/2021). Informed consent was waived.

High flow nasal cannula was instituted if arterial oxygen partial pressure to fractional inspired oxygen ($\text{PaO}_2/\text{FiO}_2$) \leq 200 mmHg with $\text{FiO}_2 > 0.4$, respiratory rate (RR) \geq 25cpm and/or sings of respiratory distress. Continuous positive airway pressure and NIV was started if $\text{SpO}_2 < 92\%$, RR \geq 25bpm and/or sings of respiratory distress in patients with HFNC failure or *ad initium* if HFNC failure was expected. Arterial oxygen partial pressure to fractional inspired oxygen ratio was accessed before NRS institution. In patients with HFNC failure who increased support to CPAP/NIV, the $\text{PaO}_2/\text{FiO}_2$ considered was the one before CPAP/NIV. Noninvasive respiratory support settings were adjusted to maintain SpO_2 92–96%. Continuous positive airway pressure and NIV was delivered by oronasal mask. All patients had a “do intubate” (DI) or “do not intubate” (DNI) order defined at admission. Baseline patient’s characteristics were compared according to NRS technique (HFNC vs. CPAP/NIV). The success rate was defined by invasive mechanical ventilation (IMV)-free survival. Several outcomes were recorded: length of stay, complications, need for endotracheal intubation (ETI) and

mortality. The association between NRS and outcomes was calculated using a logistic regression model adjusted for age, DNI order and $\text{PaO}_2/\text{FiO}_2$. A two-sided test of <0.05 was considered statistically significant.

190 out of 1748 hospitalized patients were treated with NRS in RICU. Table 1 summarizes patient’s characteristics and treatment.

50 patients needed ICU admission, 25.2% in HFNC group and 29.4% in CPAP/NIV group ($p = 0.366$). Considering only DI patients, 42.0% were escalated to ICU. Time from NRS to IMV was 3.5 ± 3.3 and 3.9 ± 2.8 days in survivors and deceased patients, respectively ($p = 0.724$). In-RICU and in-hospital mortality were 24.2% and 36.3%, respectively. In DI patients, there were no deaths in RICU and in-hospital mortality was 16.0%. In DNI patients, mortality rate was 50.0% and 58.9% in-RICU and in-hospital, correspondingly. Globally, 63.7% survived hospitalization, 53.2% exclusively treated with NRS techniques in RICU.

Table 2 illustrates outcomes according to NRS. In HFNC group, 61.9% were successful weaned and 27.1% needed ETI. The success rate in DI and DNI patients was 68.2% and 51.9%, respectively ($p < 0.001$). In-hospital mortality was 27.3% (14.1% for DI vs. 48.1% for DNI patients, $p < 0.001$). In CPAP/NIV group, CPAP was the preferred technique (56.9%). 29.4% were successfully weaned and 53.3% needed ETI. The success rate in DI and DNI patients was 40.0% and 25.0%, respectively ($p = 0.005$). In-hospital mortality was 60.8% (26.7% in DI vs. 75.0% in DNI patients, $p = 0.001$).

During the study period, our hospital received 10% of national cases of COVID-19. 10.9% were treated in RICU and 50% were successfully managed with NRS.

Considering patients with DI order, ICU admission was avoided in almost 60% and only a third needed ETI. Delays in ETI have prognostic impact and it has been suggested that NRS might have contributed to the problem. Time to IMV was similar in survivors and deceased patients. Moreover, casualties in RICU were not reported and in-hospital mortality was lower than previously described^{5,6}, supporting strategy safeness.

In-hospital mortality was 36.6%, higher than in other series.^{5,7,8} It is important to note that, in our sample, ARF was severe and almost 50% were DNI patients. Interestingly, 41% of DNI patients survived hospitalization supporting the role of NRS in patients with therapeutic ceiling.

We report a success rate of 62% in HFNC group, with a survival greater than 50% in DNI patients. In CPAP/NIV treatment group, success was achieved in 30%. Patients in this

<https://doi.org/10.1016/j.pulmoe.2021.09.002>

2531-0437/© 2021 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1 Demographic and clinical characteristics of the study population and according to cohort.

	Total	Cohort		p-value
		HFNC	CPAP/NIV	
Patients	190 (100)	139 (73.2)	51 (26.8)	
Age (years)	66.7 (11.8)	65.7 (12.2)	69.6 (10.2)	0.043
Male gender	130 (68.4)	95 (68.3)	35 (68.6)	0.970
<i>Do not intubate</i> order	90 (47.4)	54 (38.8)	36 (70.6)	<0.001
Comorbidities				
Charlson comorbidity index (points)	3.3 (2.0)	3.2 (2.1)	3.6 (1.7)	0.271
Hypertension	127 (66.8)	87 (62.6)	40 (78.4)	0.026
Dyslipidemia	122 (64.2)	92 (66.2)	30 (58.8)	0.380
Body mass index (Kg/m ²)	28.6 (5.9)	28.2 (5.7)	29.5 (6.2)	0.174
Diabetes	65 (34.2)	47 (33.8)	18 (35.3)	0.849
Heart failure	30 (15.8)	19 (13.7)	11 (21.6)	0.186
Stroke	14 (7.4)	11(7.9)	3 (5.9)	0.763
Chronic kidney disease	12 (6.3)	8 (5.8)	4 (7.8)	0.736
COPD	11 (5.8)	8 (5.8)	3 (5.9)	1.000
Length of symptoms (days)	8.1 (3.7)	7.9 (3.8)	8.6 (3.3)	0.288
Laboratory findings				
PaO ₂ /FiO ₂ (mmHg)	98.3 (67.5)	108.9 (76.3)	70.9 (18.1)	<0.001
Lymphocytes count (10 ⁹ cells per L)	0.7 (0.7)	0.7 (0.8)	0.7 (0.5)	0.526
Platelet count (10 ⁹ cells per L)	185.2 (72.1)	184.6 (71.3)	186.8 (74.7)	0.850
C-reactive protein (mg/L)	191.0 (95.6)	183.5 (88.7)	211.5 (110.6)	0.073
Procalcitonin (ng/mL)	3.3 (15.3)	2.2 (7.1)	6.4 (27.5)	0.103
Ferritin > 1500 (ng/mL)	72 (40.0)	54 (38.9)	18 (35.3)	0.680
Lactate dehydrogenase (U/L)	503.6 (234.5)	465.1 (191.9)	609.7 (302.1)	<0.001
Interleukin-6 (pg/mL)	238.2 (652.3)	199.3 (591.2)	350.5 (800.1)	0.176
D-dimer (μg/mL)	4876.0 (10374.2)	4043.1 (9235.0)	7221.5 (12884.5)	0.065
Treatment				
Steroids	185 (97.4)	134 (96.4)	51 (100.0)	0.170
Remdesivir	29 (15.3)	28 (20.1)	1 (2.0)	0.001
NRS parameters and mode				
Maximum FiO ₂		0.9 (0.1)	1.0 (0.1)	-
Maximum flow (L)		59.2 (1.0)	-	-
Maximum CPAP/EPAP (cmH ₂ O)		-	10.0 (1.9)	-
Maximum IPAP (cmH ₂ O)		-	14.8 (2.4)	-
Length of treatment (days)		5.5 (4.4)	5.2 (4.3)	-

Data are presented as number (percentages) or mean (standard deviation) as appropriate. HFNC: high flow nasal cannula; CPAP: continuous positive airway pressure; NIV: noninvasive ventilation; COPD: Chronic obstructive pulmonary disease; PaO₂/FiO₂: arterial oxygen tension /inspiratory oxygen fraction. NRS: noninvasive respiratory support. EPAP: expiratory positive airway pressure. IPAP: inspiratory positive airway pressure.

group were older, had more severe ARF and 71% were *DNI*. Mortality rates in patients treated outside-ICU, in whom NIV was the therapeutic ceiling, reached 76% in previously reports, which is in line with our findings.^{6,7,9} Nevertheless, CPAP/NIV prevented IMV in 40% of the candidates, with mortality rates similar to published data.¹⁰

The difference in ETI and mortality rates between groups disappeared after adjustment for confounders, emphasising that outcomes don't rely on the NRS technique. Complications were infrequent. Pneumothorax/pneumomediastinum is reported in 2% of ICU treated patients.¹¹ Barotrauma occurred in both groups equally after adjustment for confounders, suggesting that underlying disease severity might play a role.

Our study has limitations: the decision to start on a specific NRS technique greatly relied on equipment availability and is single-centered with a limited sample.

To the best of our knowledge this is the first prospective study on NRS outside-ICU in COVID-19 pneumonia, conducted

in one of the Portuguese regions that was most affected. Both HFNC and CPAP/NIV seem to be equally feasible and outside-ICU should be considered for selected patients in resource-constrained settings.

Contributions of the authors

Lígia Rodrigues Santos, Rafaela Gonçalves Lopes, Ana Silva Rocha, Marta Dalila Martins, Teresa C. Guimarães, Mariana Meireles and Helena Vilaça collected the clinical and biological data from the files.

Mariana Meireles and Helena Vilaça, provided assistance for statistical analysis.

Lígia Rodrigues Santos, Rafaela Gonçalves Lopes, Mariana Meireles and Helena Vilaça wrote the manuscript.

Alice Castro, Mari Mesquita revised the manuscript

All the authors have checked the manuscript.

Table 2 Clinical outcomes and relative probability according to noninvasive respiratory support technique.

	Total	HFNC	CPAP/NIV	OR (95% CI)	p-value
Length of stay (days)	15.2 (13.0)	15.4 (13.6)	14.7 (11.3)	0.99 (0.97-1.02)	0.740
Technique complications					
Facial ulcers	3 (5.9)	-	3 (5.9)	-	-
Intolerance	3 (5.9)	0 (0.0)	3 (5.9)	-	-
Aspiration	0 (0.0)	-	0 (0.0)	-	-
Pneumothorax Pneumomediastinum	7 (3.7)	3 (2.6)	4 (7.8)	-	-
Crude				3.86 (0.833-17.88)	0.084
Adjusted [#]				1.76 (0.29-10.84)	0.541
ETI	31 (31.0)	23 (27.1)	8 (53.3)		
Crude				3.08 (1.00-9.46)	0.049
Adjusted [†]				1.82 (0.47-7.02)	0.388
Hospital mortality	69 (36.3)	38 (27.3)	31 (60.8)		
Crude				4.12 (2.10-8.09)	<0.001
Adjusted [#]				1.27 (0.27-5.97)	0.765

Data are presented as number (percentages) or mean (standard deviation) as appropriate. HFNC: high flow nasal cannula; CPAP: continuous positive airway pressure; NIV: noninvasive ventilation; ETI: endotracheal intubation.

[#] adjusted for age, arterial oxygen tension/inspiratory oxygen fraction ratio and “do not intubate” order.

[†] adjusted for age and arterial oxygen tension/inspiratory oxygen fraction ratio.

Conflicts of interest

The authors declare that they have no conflict of interests.

Acknowledgements

We would like to thank all healthcare professionals that have been working in RICU during this pandemic.

We would also like to thank the ICU team for all the support provided.

References

- Crimi C, Noto A, Cortegiani A, et al. Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections. *Minerva Anestesiologica*. 2020;86(11):1190–204. <https://doi.org/10.23736/S0375-9393.20.14785-0>.
- Winck JC, Ambrosino N. COVID-19 pandemic and noninvasive respiratory management: every Goliath needs a David. An evidence based evaluation of problems. *Pulmonology*. 2020;26(4):213–20. <https://doi.org/10.1016/j.pulmoe.2020.04.013>.
- Ippolito M, Vitale F, Accurso G, et al. Medical masks and respirators for the protection of healthcare workers from SARS-CoV-2 and other viruses. *Pulmonology*. 2020;26(4):204–12. <https://doi.org/10.1016/j.pulmoe.2020.04.009>.
- Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study. *EclinicalMedicine*. 2020;28:100570. <https://doi.org/10.1016/j.eclinm.2020.100570>.
- Franco C, Facciolo N, Tonelli R, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. *Eur Respir J*. 2020;56(5):2002130. <https://doi.org/10.1183/13993003.02130-2020>.
- Faraone A, Beltrame C, Crociani A, et al. Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-associated acute hypoxemic respiratory failure: a single center, non-ICU setting experience. *Intern Emerg Med*. 2020: 1–8. <https://doi.org/10.1007/s11739-020-02562-2>.
- Bellani G, Grasselli G, Cecconi M, et al. Noninvasive ventilatory support of patients with COVID-19 outside the intensive care units (WARd-COVID). *Ann Am Thorac Soc*. 2021;18(6):1020–6. <https://doi.org/10.1513/AnnalsATS.202008-1080OC>.
- Guy T, Créac’hacdec A, Ricordel C, et al. High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU. *Eur Respir J*. 2020;56(5):2001154. <https://doi.org/10.1183/13993003.01154-2020>.
- Coppadoro A, Benini A, Fruscio R, et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. *Crit Care*. 2021;25(1):80. <https://doi.org/10.1186/s13054-021-03502-y>.
- Soares 3rd WE, Schoenfeld EM, Visintainer P, et al. Safety assessment of a noninvasive respiratory protocol for adults with COVID-19. *J Hosp Med*. 2020;15(12):734–8. <https://doi.org/10.12788/jhm.3548>.
- Martinelli AW, Ingle T, Newman J, et al. COVID-19 and pneumothorax: a multicentre retrospective case series. *Eur Respir J*. 2020;56(5):2002697. <https://doi.org/10.1183/13993003.02697-2020>.

L. Rodrigues Santos^a, R. Gonçalves Lopes^b, A.S. Rocha^a, M.D. Martins^a, T.C. Guimarães^c, M. Meireles^{a,*}, H. Vilaça^a, A. Castro^a, M. Mesquita^a

^a Department of Internal Medicine, Centro Hospitalar do Tâmega e Sousa, Avenida do Hospital Padre Américo 210, 4564-007 Penafiel, Portugal

^b Department of Cardiology, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal

^c Department of Intensive Care Medicine, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal

* Corresponding author.

E-mail address: mra.meireles@gmail.com (M. Meireles).

Received 18 July 2021; Accepted 8 September 2021

Available online 2 October 2021